22nd European Congress on Alternatives to Animal Testing, August 25-28 2019, University of Linz, Austria

Oral presentations per session

(vers. 26.09.2019)

Abstractbook is online!

K1 Opening & Keynote Lecture I (plenary)
Thursday, 10 October 2019
    Welcome addresses
Dagmar Jírová, Vice-President of EUSAAT, CZ-Prague &
Horst Spielmann, Chair of the Scientific Committee, DE-Berlin
    Keynote Lecture I
Update on human stem cells - scientific, ethical and legal challenges
Jürgen Hescheler, DE-Cologne
K2 Keynote Lecture II (plenary)
Friday, 11 October 2019
    Implementing Directive 2010/63/EU - current status and next steps
Susanna Louhimies, BE-Brussels
K3 Keynote Lecture III (plenary)
Saturday, 12 October 2019
    Human Artificial Lymph Node Model (HuALN) for biopharmaceutical testing and disease modelling in vitro
Christoph Giese, DE-Berlin
K4 Keynote Lecture IV (plenary)
Sunday, 13 October 2019
    Challenging FDA’s requirement for long term studies in dogs for the safety assessment of drugs and pharmaceuticals
Mihael H. Polymeropoulos, US-Washington DC
Björn Ekwall Award Lecture (plenary)
Friday, 12 October 2019
    Serum-free media contribute to better reproducibility in in vitro research 
Jan van der Valk, NL-Utrecht
1.1 3D Models & multi-organ-chips (MOC), human-organ-chips (HOC) - I
Thursday, 10 October 2019
294   Microphysiological flux balance platform unravels the dynamics of drug induced steatosis
Avner Ehrlich, IL-Jerusalem
awarded with the YSTA 2019
316   3D CNS model of iPSCs derived neuron and glia for high-throughput neurotoxicity screening in Mimetas’ OrganoPlate®
Chiwan Chiang, NL-Leiden
409   An in vitro fracture hematoma model as a tool for preclinical drug testing
Moritz Pfeiffenberger, DE-Berlin
465   The combination of 3D human cancer tissues and fluid-dynamic drug administration as winning strategy for in vitro drug efficacy testing
Silvia Scaglione, IT-Genoa
480   Integrating Organ-on-a-Chip devices on a multimodal, microfluidic platform
Eva Zittel, DE-Karlsruhe
awarded with the YSTA 2019
1.2 3D Models & multi-organ-chips (MOC), human-organ-chips (HOC) - II
Saturday, 12 October 2019
487   Beating organs-on-chip as advanced tools in drug screening: engineered in vitro models of human organs and diseases
Roberta Visone, IT-Milan
awarded with the YSTA 2019
498   Development of 3D skin model and 3D skin infection model, as advanced testing tools for the bio-evaluation of novel antimicrobial biomaterials for treating infected wounds
Ayesha Idrees, IT-Turin
awarded with the YSTA 2019
526   Biology-Inspired Micro-physiological System Approaches to Solve the Prediction Dilemma of Substance Testing
Horst Spielmann, DE-Berlin
530   Brief introduction of user-driven microphysiological system development in Japan
Toshiyuki Kanamori, JP-Tsukuba
535   3D in vitro scaffold based cell model of neuroblastoma for evaluating genotoxic and miRNA-targeted therapeutics
Olga Piskareva, IR-Dublin
2.1 3R Centers in Europe & international - national and local centers - I
Thursday, 10 October 2019

331   Norecopa: working to advance harmonisation and dissemination of best practice in animal research and testing 
Adrian Smith, NO-Oslo
388   Italian Centro3Rs commitment: 1 year after the opening of the activities
Anna Maria Bassi, IT-Genoa
398   At crossroads between regulation, science and industrial application: the EPAA, a public-private initiative for the 3Rs
Franz Lamplmair, BE-Brussels
434   A Society for Alternatives to Animal Experiments in India: An Update
Mohammad Abdulkader Akbarsha, IN-Tiruchirappalli
457   Austria goes 3R - The RepRefRed Society
Birgit Reininger-Gutmann, AT-Graz
2.2 3R Centers in Europe & international - national and local centers - II
Saturday, 12 October 2019

488   Charité 3R – the 3R Center of Charité Universitätsmedizin Berlin
Annemarie Lang, DE-Berlin
517   Slovak National Platform for Three Rs (SNP 3Rs) in Science, Education, Research and Development
Helena Kandarova, SK-Bratislava
523   3Rs Center at the National Institute of Public Health in the Czech Republic
Dagmar Jírová, CZ-Prague
346   Animal experiments or humane alternatives: awareness raising campaign in Belarus
Tatsiana Hlinkina, BY-Minsk
369   Asian Consortium for Three Rs
Hajime Kojima, JP-Tokyo
3.1 3Rs in education and academia - I
Friday, 11 October 2019

383   Advancing the Three Rs education and training under a European Parliament Pilot Project
Susanna Louhimies, BE-Brussels
486   3Rs education in academia: experiences from the Swiss 3R competence centre
Chantra Eskes, CH-Bern
328   Initiatives to promote the Three Rs in education and training
Francesca Pistollato, IT-Ispra
402   3R funding of research activities 2014-2019 in Denmark by the Danish 3R centre
Lisbeth Knudsen, DK-Copenhagen
3.2 3Rs in education and academia - II
Saturday, 12 October 2019

340   Education towards non-animal approaches in basic and applied biomedical research
Kathrin Herrmann, US-Baltimore
381   Refinement in education
Györgyi Szabó
, HU-Budapest
513   Innovations in veterinary education and training and the feasibility of full replacement
Nick Jukes, UK-Leicester
520   Time to rethink the 3Rs after 60 years. Time for just 1R: Replacement and non-animal research
Candida Nastrucci, IT-Rome
4 Advanced safety testing of cosmetics & consumer products and alternatives to animal testing in food safety, nutrition and efficacy
Saturday, 12 October 2019

337   Cosmetic perfumes and their potential of endocrine disruption, sensitization and genotoxicity
Marketa Dvorakova, CZ-Prague
380   Safety testing of adult novelties using methods in vitro
Lada Bělastová, CZ-Prague
awarded with the YSTA 2019
451   Collaboration for non-animal cosmetic safety assessment globally by 2023
Paul Russell, UK-Sharnbrook
330   Gluconeogenic processes in a bovine liver cell line offered short chain fatty acids
Anna-Maria Sittel, DE-Leipzig
528   Demonstration of different intestinal absorption mechanisms of lactulose and mannitol by using 3D tissue inserts within fluidic multi-chamber devices
Silvia Scaglione, IT-Genoa
paid advertising

Banner MatTek

5 An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment: Results of the in3 project
Thursday, 10 October 2019
507   An introduction to the in3 project
Maxime Culot
, FR-Lens
Paul Jennings
, NL-Amsterdam
429   In3 Project: a European initiative to evaluate toxicity of chemicals using iPSCs derived in vitro models: Focus on blood brain barrier models for neurotoxicity assessment
Sara Wellens, FR-Lens
508   Study the effect of cyclosporin A on functionality of endothelial cells differentiated from iPS cells as in vitro toxicology model system
Zahra Mazidi, AT-Vienna
509   Evaluation of human induced Pluripotent Stem Cell derived podocyte-like cells for toxicity testing
Cormac Murphy, NL-Amsterdam
493   In vitro distribution kinetics and neurotoxicity of the cardiac drug amiodarone in the iPSC-derived human 3D model BrainSpheres
Carolina Nunes, CH-Lausanne 
6 Biological barriers
Saturday, 12 October 2019

360   Apparent permeability coefficients of ciprofloxacin in human lung epithelial cells appropriately predict bioavailability after inhalation exposure
Nico Sonnenschein, DE-Hannover
481   ALT4EI: Assessment of eye irritating potential of 59 chemicals using EpiOcular™ time-to-toxicity (EpiOcular ET-50) neat and dilution protocols
Silvia Letasiova, SK-Bratislava
432   The Blood-Saliva Barrier: An optimized in vitro model of the oral epithelium and its relevance for biomarker research
Grace Lin, AT-Vienna
506   Modeling of drug toxicity and permeability using the reconstructed 3D model of small intestine
Jan Markus, SK-Bratislava
496   Using ex vivo human skin for the assessment of drug transport across the skin barrier with label-free Raman microscopy
Nathalie Jung, DE-Frankfurt/Main
awarded with the YSTA 2019
7.1 Disease models using HUMAN cells, tissues and organs - I
Friday, 11 October 2019

304   Human-based T cell-skin models for graft-versus-host disease
Maximiliane Wussmann, DE-Würzburg
311   Neuroprotection via an iNOS-inhibitor in a porcine retina organ culture model
Stephanie C Joachim, DE-Bochum
355   Simulating an arthritic joint in vitro by combining multiple tissue components
Alexandra Damerau, DE-Berlin
379   Development of an in vitro trabecular human bone model integrated in a perfusion system to simulate glucocorticoid-induced osteoporosis
Karoline Diesing, DE-Berlin
awarded with the YSTA 2019
459   Adding DIMENSIONS and a COMPLEMENT-ary view on HIV-1 transmission
Doris Wilflingseder, AT-Innsbruck
7.2 Disease models using HUMAN cells, tissues and organs - II
Sunday, 13 October 2019

482   Cultivation of primary melanoma cells with human platelet lysate or bovine serum show different phenotypic and genotypic characteristics
Beate Rinner, AT-Graz
484   In vitro models of human cardiac fibrotic tissue based on bioartificial scaffolds
Irene Carmagnola, IT-Turin
533   HepaRG™: an integrated model for studying bile canalicular functions and dysfunctions for studying Cholestasis Toxicity
Ashwani Sharma, FR-Saint-Grégoire
534   Sensitive and automated assessment of DNA strand break by AUREA gTOXXs in HepaRGTM
Dirk Dressler, DE-Esslingen
507   Transcriptomic, metabolic and toxicological comparison of the human liver derived HepaRG with the human kidney derived RPTEC/TERT1 cells
Paul Jennings, NL-Amsterdam 
8 Ecotoxicology
Friday, 11 October 2019

335   Using PLHC-1 topminnow liver cells to characterize and predict the effect of plastic additives in fish
Cinta Porte, ES-Barcelona
384   Reliable and representative in silico predictions of freshwater ecotoxicological hazardous concentrations
Mélanie Douziech, NL-Nijmegen
394   From initiation to implementation: the RTgill-W1 cell line assay to predict fish acute toxicity of water samples and chemicals (ISO21115)
Melanie Fischer, CH-Dübendorf
395   In vivo measurement of 7-methoxycoumarin-O-demethylase activity in zebrafish (Danio rerio) embryos
Ann-Kathrin Lörracher, DE-Heidelberg
453   Gene expression upon immune challenge in a fish intestinal in vitro model
Stephan Fischer, CH-Wallisellen
9.1 Efficacy and safety testing of drugs, medical devices & biopharmaceutics - I
Thursday, 10 October 2019

442   Implementing 3Rs by the pharmaceutical industry
Kirsty Reid, BE-Brussels
411   Drivers for the pharmaceutical industry to adopt human stem-cell based models
Ard Teisman
, BE-Beerse
458   Replacement and Reduction examples from Novo Nordisk
Thomas Bertelsen
, DK-Maaloev
454   From a 3Rs intent to a company's strategy: perspective from the Industry
Shahjahan Shaid
, BE-Wavre
313   Stakeholder Collaboration to Advance Human-Relevant Nonclinical Methods for Drug Development in the United States
Elizabeth Baker, US-Washington DC 
9.2 Efficacy and safety testing of drugs, medical devices & biopharmaceutics - II
Saturday, 12 October 2019
466   Replacement of the potency assay for tick borne encephalitis virus vaccines
Dieter Pullirsch, AT-Vienna
478   Development, pre-validation and validation of the EpiDerm in vitro skin irritation protocol for the medical devices extracts
Silvia Letasiova, SK-Bratislava
502   Orally inhaled drug products – The strengths and weaknesses of simplified in vitro methods
Marius Hittinger, DE-Saarbrücken
518   Development of recombinant antibodies to replace animal sera
Maximilian Ruschig, DE-Braunschweig
399   Current status of the implementation of new methods in cardiotoxicity safety testing
Christiane Hohensee
, DE-Erkrath  
9.3 Efficacy and safety testing of drugs, medical devices & biopharmaceutics - III
Friday, 11 October 2019

532   Vaccine batch to vaccine batch comparison by consistency testing (VAC2VAC)
Coenraad Hendriksen, NL-Bilthoven
338   Proteomic analysis of canine leptospira vaccines
Thomas Schuenborg
, DE-Langen
345   Development of an OECD Test Guideline for Androgen Receptor Transactivation Assays (ARTAs)
Anne Milcamps
, IT-Ispra
529   Improving Drug Toxicity Assays through the Oxygen-dependent Induction of Metabolic Zonation in Primary Rat Hepatocytes
Benedikt Scheidecker
, JP-Tokyo
366   3R-alternatives to skin testing of bovine PPD tuberculins
Elisabeth Balks
, DE-Langen
10 Ethical & legal issues
Friday, 11 October 2019

412   Normalizing the unthinkable: The report of the Oxford Centre for Animal Ethics
Clair Linzey, UK-Oxford
501   Modernising research and regulatory policies to advance human health
Julia Baines, UK-London
521   The impact of closure of specialised mouse research facilities
Lindsay Marshall, US-Washington DC
389   Towards veterinary ethics
Kerstin Weich
, AT-Vienna
387   Why are alternative methods (not) chosen? Presentation of a project on the investigation of value judgments for or against alternatives in animal testing in basic research
Ines Pietschmann, DE-Hannover
 paid advertising

Banner evercyte

11 Free communications
Sunday, 13 October 2019
341   Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? A systematic analysis of opinion papers
Pandora Pound, UK-Kingsbridge
342   California Cruelty-Free Cosmetics Act establishes first North American law banning the sale of animal tested cosmetics and ingredients
Elizabeth Baker, US-Washington DC
417   When the co-culture does not do what it is supposed to do – a step “back” to ex vivo models
Sabrina Schnur, DE-Saarbrücken
511   Regulation of Endocrine Disruptors: REACH may change, but will the science evolve?
Emma Grange, UK-London
421   Repeating past mistakes: The banality and futility of nowadays cigarette smoke-related animal experimentation
Dilyana Filipova, DE-Cologne
12 Implementing EU Dir 63/2010 - update
Friday, 11 October 2019

382   Project evaluation – importance of a coherent and consistent approach
Susanna Louhimies
, BE-Brussels
452   A user perspective towards improving the processes of project evaluation
Kirsty Reid, BE-Brussels
310   Thematic review of animals used for scientific purposes: a mechanism for advancing replacement
Christina Dodkin
, UK-London
334   Initiative for better access and digitalisation to EU agencies safety data
Francois Busquet, BE-Ixelles
362   Animalstudyregistry.org – a federal database for preregistration of animal research
Justyna Chmielewska, DE-Berlin
13 In silico models: toxicology & efficacy of drugs, chemicals & cosmetics, new approaches for biomedical research
Saturday, 12 October 2019

(This session is sponsored by the Lush Prize.)
307   The many cards up ‘computational sleeves’: reshaping in silico tools used in drug discovery to design safer and functional chemicals
Jakub Kostal, US-Washington DC
352   Combining in vitro and in silico modelling to simulate cartilage degradation during osteoarthritis
Annemarie Lang, DE-Berlin
302   Using big data for developing QSAR models to predict interaction of chemicals with neuronal proteins
Yaroslav Chushak, US-Dayton
348   Using the OECD QSAR toolbox as an in silico modelling method for computational aquatic toxicology of endocrine disruptors 
Dahye Kim, DE-Saarbrücken
444   What can (Q)SAR modelling can tell us about fish toxicity?
Pascal Bicherel, FR-L’Isle D’Abeau
14 Initiative for implementing serum free culture media
Friday, 11 October 2019

424   There is no ethical justification for the use of fetal bovine serum (FBS)
Tilo Weber
, DE-Neubiberg
410   Using platelet-rich human platelet lysate to substitute fetal calf serum for cultivation of mesenchymal stromal cells
Moritz Pfeiffenberger, DE-Berlin
542   A totally defined animal product free cell culture medium for a 3D human tumour out-side the body 
Stina Oredsson, SE-Lund
425   Björn Ekwall Memorial Award Lecture
Serum-free media contribute to better reproducibility in in vitro research 
Jan van der Valk
, NL-Utrecht
15 In vitro techniques for CNS toxicity and disease studies
Thursday, 10 October 2019

323   An AOP-driven assessment of developmental neurotoxicity induced by chemical mixtures using human iPSC-derived neuronal/glial cultures
Francesca Pistollato, IT-Ispra
495   In vitro neurotoxicity testing: functional neuron-specific endpoints
Manuela Marcoli, IT-Genoa
422   The relevance of shear stress for in-vitro models of the human blood-brain barrier: a comparative study
Anna Gerhartl, AT-Vienna
499   Modelling the human blood-brain-barrier microvasculature and nanocarrier transport on a microfluidic chip
Marco Campisi, IT-Turin
awarded with the YSTA 2019
16.1 Reduction & refinement - I
Friday, 11 October 2019
386   Moving transparency to the next level – Non-technical project summaries under Directive 2010/63/EU
Susanna Louhimies, BE-Brussels
298   Does the stress of laboratory life and experimentation on animals adversely affect research data?
Jarrod Bailey, UK-London
336   Full implementation of refinement methods in practice through education and training
Kathrin Herrmann
, US-Baltimore
312   Towards an automated surveillance of well-being in mice using deep learning
Katharina Hohlbaum, DE-Berlin
awarded with the YSTA 2019
350   Clicker training for small rodents – cognitive enrichment and beyond
Nadine Baumgart, DE-Mainz
16.2 Reduction & refinement - II
Saturday, 12 October 2019
359   Ethical justification of animal experiments in Germany
Christa Thöne-Reineke, DE-Berlin
443   The Animal Protection Quality Certificate. A tool to assess refinement methods in animal experiments 
Roberto Plasenzotti, AT-Vienna
456   Developing a new simulator of the rat for laboratory animal training courses using 3D printing
Giuliano Mario Corte, DE-Berlin
531   Viva3R!
Stefanie Schindler, DE-Konstanz
414   Refinement in laboratory animal science education – An inquiry concerning the use of rat and mouse simulators among LAS instructors 
Melanie Humpenöder, DE-Berlin
17 Replacement - advanced technologies
Friday, 11 October 2019

308   Transitioning from mammalian animal testing to non-animal testing using the zebrafish (Brachydanio rerio) embryo as a whole organism model for regulatory decision-making in chemical risk assessments
Cindy Woodland, CA-Ottawa
450   The importance of data quality and governance in the acceptance of Next Generation risk Assessment (NGRA) approaches
Paul Russel, UK-Sharnbrook
463   Bioprinting of 3D organ models for virus and cancer research 
Jens Kurreck, DE-Berlin
492   Combining fluidic chips and 3D bioprinting - an approach to study tumor-microenvironment and angiogenesis in vitro
Michael J. Ausserlechner, AT-Innsbruck
440   The Need for Non-Animal Recombinant Antitoxins
Dipti Kapoor, IN-Dehli
18 Specific endpoints of toxicity
Sunday, 13 October 2019

297   Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations
Jarrod Bailey, UK-London
426   Interpreting irregular LLNA data for evaluation of non-animal methods for skin sensitization
David Roberts, UK-Liverpool
371   OECD DRP on in vitro assays in reproductive toxicology
Hajime Kojima
, JP-Kawasaki
525   Evaluation of in vitro embryotoxicity tests for Chinese herbal medicines
Lucia Li
, CN-Hangzhou & Horst Spielmann, DE-Berlin
19 Stem cell models and technology (hIPS, ES, mES, mIPS…)
Thursday, 10 October 2019

322   Human urine as a non-invasive source of kidney progenitor cells amenable for nephrotoxicity studies
James Adjaye, DE-Düsseldorf
325   Advancing chemical safety assessments through integration of population-based in vitro models and computational methods 
Fabian Grimm, US-Annandale
536   Of mice, chicken and human induced pluripotent stem cells: studying midbrain dopaminergic neuron development and survival in the context of Parkinson’s Disease
Nilima Prakash, DE-Hamm
439   Generation of hepatic organoids from human induced pluripotent stem cells
Hyemin Kim, KR-Daejeon
477   Generation of functional macrophages from human induced pluripotent stem cells
SeongYea Jo, KR-Daejeon
20 How to account for uncertainties of reference methods & data?
Sunday, 13 October 2019

357   Accounting of uncertainties for complex endpoints: What do we want to know?
Martin Paparella, AT-Innsbruck
449   Assessment of uncertainties – ECVAM experience from recent in-vitro validation studies
Roman Liska, IT-Ispra
361   Fish acute toxicity: Which data do we need and where do we get these from?
Thomas Braunbeck, DE-Heidelberg
391   On the uncertainty of toxicological methods: Quantifying the borderline range of prediction models and implications for decision-making
Silke Gabbert, NL-Wageningen
479   Animal free development, testing, parameterisation and calibration of human PBPK models for two plasticisers
Kevin McNally, UK-Buxton
21 Animal experimentation: working towards a paradigm change
(inspired by the book with the same title, eds: K. Herrmann and K. Jayne)
Sunday, 13 October 2019

299   CRISPR-mediated gene editing: scientific and ethical issues
Jarrod Bailey, UK-London
385   Refinement on the way towards Replacement: Are we doing what we can?
Kathrin Herrmann, US-Baltimore
403   Animal research for Alzheimer's Disease: failures of science and ethics
Francesca Pistollato, IT-Ispra
543   Replacing animal tests to improve safety for humans
Jan Turner, UK-Kingsbridge
544   How can the final goal of completely replacing animal procedures successfully be achieved?
Carolin Spicher, DE-Munich
22.1 'Young Scientists' session - I
Saturday, 12 October 2019

545   Session keynote
Similarity of a career in the field of 3Rs and a Trans-Alpine Crossing
Barbara Birk
, DE-Ludwigshafen
332   P. aeruginosa infected co-culture of human cystic fibrosis bronchial epithelial cells as a preclinical test system for anti-infectives
Justus Horstmann
, DE-Saarbrücken
awarded with the YSTA 2019
418   Development of a test system for the investigation of the pulmonary mucus barrier
Nina Grzeschik, DE-Saarbrücken
445   Engineering in vitro Lung Microbiota for Antimicrobial Treatment
Daniela Pacheco, IT-Milan
awarded with the YSTA 2019
467   Differentiation of motor neurons for in vitro potency testing of Botulinum Neurotoxins
Maren Schenke, DE-Hannover
awarded with the YSTA 2019
22.2 'Young Scientists' session - II
Sunday, 13 October 2019

505   A novel model for mechanical assessment of biomaterials
Constantinos Voniatis
, HU-Budapest
awarded with the YSTA 2019
504   A reconstructed human skin model containing macrophages to set up a delayed wound healing model of cutaneous leishmaniasis
Priscila Schilrreff
, AR-Buenos Aires
awarded with the YSTA 2019
433   An innovative in vitro physiological relevant model as a tool to test therapeutic strategies for glaucoma
Stefania Vernazza
, IT-Genoa
392   Development of a human pancreatic cell line with optogenetically controllable receptor for high content screening 
Anna Stierschneider
, AT-Krems
415   Design of experimental animal surgical models: Creation of a mouse uterus 3D-model for learning the in-utero electroporation 
Maximilian Nuber
, DE-Mainz
R1 Round Table I (plenary)
International impact of closing research animal facilities in Europe
Thursday, 10 October 2019

R3 Round Table II (plenary)
Establishing an International 3Rs Centers Network
Saturday, 12 October 2019
P1 Poster Session I
Friday, 11 October 2019

    Survey of the posters with presence of the authors.
The titles and authors of this poster session I will be published separately.
All posters will be present during all days of the congress.
P2 Poster Session II
Saturday, 12 October 2019

    Survey of the posters with presence of the authors.
The titles and authors of this poster session II will be published separately.
All posters will be present during all days of the congress.